APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Angiotensin Converting Enzyme (ACE) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173963670321 December 2025193 pages

Choose your research edition.

Industry ResearchAngiotensin Converting Enzyme (ACE) Inhibitors Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Angiotensin Converting Enzyme (ACE) Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Angiotensin Converting Enzyme (ACE) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiotensin Converting Enzyme (ACE) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiotensin Converting Enzyme (ACE) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Angiotensin Converting Enzyme (ACE) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiotensin Converting Enzyme (ACE) Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiotensin Converting Enzyme (ACE) Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiotensin Converting Enzyme (ACE) Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiotensin Converting Enzyme (ACE) Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

Abbott Laboratories

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Type

Dicarboxylate-containing Agents

Sulfhydryl-containing Agents

Phosphonate-containing Agents

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Application

Cardiovascular Diseases

Kidney Diseases

Hypertension

Other

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Converting Enzyme (ACE) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Converting Enzyme (ACE) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Converting Enzyme (ACE) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiotensin Converting Enzyme (ACE) Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Angiotensin Converting Enzyme (ACE) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Angiotensin Converting Enzyme (ACE) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Angiotensin Converting Enzyme (ACE) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Trends Table 2. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Drivers Table 3. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Opportunities and Challenges Table 4. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Restraints Table 5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers Table 9. Global Angiotensin Converting Enzyme (ACE) Inhibitors Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Angiotensin Converting Enzyme (ACE) Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Angiotensin Converting Enzyme (ACE) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers, Product Type & Application Table 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Dicarboxylate-containing Agents Table 17. Major Manufacturers of Sulfhydryl-containing Agents Table 18. Major Manufacturers of Phosphonate-containing Agents Table 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 20. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 21. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 22. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2026) Table 23. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2027-2032) Table 24. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 25. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (k tons) Table 26. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (k tons) Table 27. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2026) Table 28. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Cardiovascular Diseases Table 30. Major Manufacturers of Kidney Diseases Table 31. Major Manufacturers of Hypertension Table 32. Major Manufacturers of Other Table 33. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 34. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 35. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 36. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 39. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (k tons) Table 40. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (k tons) Table 41. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 44. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2021-2026) & (k tons) Table 45. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecasted by Region (2027-2032) & (k tons) Table 47. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 49. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 50. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 51. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 52. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 53. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 54. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 55. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 56. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 57. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 58. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 59. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 60. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Teva Pharmaceutical Company Information Table 66. Teva Pharmaceutical Business Overview Table 67. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 69. Teva Pharmaceutical Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 74. Sanofi Recent Development Table 75. Jhonson and Johnson Company Information Table 76. Jhonson and Johnson Business Overview Table 77. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 79. Jhonson and Johnson Recent Development Table 80. Novartis Company Information Table 81. Novartis Business Overview Table 82. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 84. Novartis Recent Development Table 85. Merck Company Information Table 86. Merck Business Overview Table 87. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 89. Merck Recent Development Table 90. Eli Lilly Company Information Table 91. Eli Lilly Business Overview Table 92. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 94. Eli Lilly Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 99. Pfizer Recent Development Table 100. GSK Company Information Table 101. GSK Business Overview Table 102. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 104. GSK Recent Development Table 105. Bayer Company Information Table 106. Bayer Business Overview Table 107. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 109. Bayer Recent Development Table 110. Bristol-Myers Squibb Company Information Table 111. Bristol-Myers Squibb Business Overview Table 112. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 114. Bristol-Myers Squibb Recent Development Table 115. Astra Zeneca Company Information Table 116. Astra Zeneca Business Overview Table 117. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 119. Astra Zeneca Recent Development Table 120. Abbott Laboratories Company Information Table 121. Abbott Laboratories Business Overview Table 122. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 124. Abbott Laboratories Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List Table 128. Angiotensin Converting Enzyme (ACE) Inhibitors Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Angiotensin Converting Enzyme (ACE) Inhibitors Product Image Figure 2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (2021-2032) & (k tons) Figure 5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Angiotensin Converting Enzyme (ACE) Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Dicarboxylate-containing Agents Image Figure 9. Sulfhydryl-containing Agents Image Figure 10. Phosphonate-containing Agents Image Figure 11. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 12. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2032) Figure 14. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2032) Figure 17. Cardiovascular Diseases Image Figure 18. Kidney Diseases Image Figure 19. Hypertension Image Figure 20. Other Image Figure 21. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 22. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 25. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 28. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 30. Canada Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 31. Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 32. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 35. France Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 36. U.K. Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 37. Italy Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 38. Netherlands Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 39. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 42. Japan Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 43. South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 44. Southeast Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 45. India Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 46. Australia Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 47. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 48. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 50. South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 51. Saudi Arabia Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 52. Turkey Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 53. Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 54. UAE Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 55. Egypt Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Chile Angiotensin Converting Enzyme (ACE) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 57. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Angiotensin Converting Enzyme (ACE) Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Angiotensin Converting Enzyme (ACE) Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Dicarboxylate-containing Agents
  • Sulfhydryl-containing Agents
  • Phosphonate-containing Agents
Applications
  • Cardiovascular Diseases
  • Kidney Diseases
  • Hypertension
  • Other
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Dynamics
  1. 2.1 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Trends
  2. 2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Drivers
  3. 2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Restraints
3 Angiotensin Converting Enzyme (ACE) Inhibitors Market by Manufacturers
  1. 3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Angiotensin Converting Enzyme (ACE) Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Angiotensin Converting Enzyme (ACE) Inhibitors Tier 1, Tier 2, and Tier 3
4 Angiotensin Converting Enzyme (ACE) Inhibitors Market by Type
  1. 4.1 Angiotensin Converting Enzyme (ACE) Inhibitors Type Introduction
  2. 4.1.1 Dicarboxylate-containing Agents
  3. 4.1.2 Sulfhydryl-containing Agents
  4. 4.1.3 Phosphonate-containing Agents
  5. 4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type
  6. 4.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032)
  8. 4.2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2032)
  9. 4.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type
  10. 4.3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032)
  12. 4.3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2032)
5 Angiotensin Converting Enzyme (ACE) Inhibitors Market by Application
  1. 5.1 Angiotensin Converting Enzyme (ACE) Inhibitors Application Introduction
  2. 5.1.1 Cardiovascular Diseases
  3. 5.1.2 Kidney Diseases
  4. 5.1.3 Hypertension
  5. 5.1.4 Other
  6. 5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application
  7. 5.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032)
  9. 5.2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2032)
  10. 5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application
  11. 5.3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032)
  13. 5.3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region
  1. 6.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region
  1. 7.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region
  2. 7.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jhonson and Johnson
  14. 8.3.1 Jhonson and Johnson Company Information
  15. 8.3.2 Jhonson and Johnson Business Overview
  16. 8.3.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  18. 8.3.5 Jhonson and Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Astra Zeneca
  62. 8.11.1 Astra Zeneca Company Information
  63. 8.11.2 Astra Zeneca Business Overview
  64. 8.11.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  66. 8.11.5 Astra Zeneca Recent Developments
  67. 8.12 Abbott Laboratories
  68. 8.12.1 Abbott Laboratories Company Information
  69. 8.12.2 Abbott Laboratories Business Overview
  70. 8.12.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  72. 8.12.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiotensin Converting Enzyme (ACE) Inhibitors Value Chain Analysis
  2. 9.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiotensin Converting Enzyme (ACE) Inhibitors Production Mode & Process
  6. 9.2 Angiotensin Converting Enzyme (ACE) Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors
  9. 9.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst